Safety and feasibility of hospital discharge 2 days following primary percutaneous intervention for ST-segment elevation myocardial infarction

DA Jones, KS Rathod, JP Howard, S Gallagher… - Heart, 2012 - heart.bmj.com
Aim Primary percutaneous coronary intervention (PPCI) produces more effective coronary
reperfusion and allows immediate risk stratification compared with fibrinolysis. We …

Machine learning with convolutional neural networks for clinical cardiologists

JP Howard, DP Francis - Heart, 2021 - heart.bmj.com
Machine learning (ML) is a revolution in computer science and is set to change the face of
cardiology practice. In ML, humans no longer need to convert an understanding of a …

Artificial intelligence and the cardiologist: what you need to know for 2020

A de Marvao, TJW Dawes, JP Howard, DP O'Regan - Heart, 2020 - heart.bmj.com
We live in an era with unprecedented availability of clinical and biological data that include
electronic health records, wearable sensors, biomedical imaging and multiomics. The scale …

Recurrent ascites due to constrictive pericarditis

JP Howard, D Jones, P Mills, R Marley… - Frontline …, 2012 - fg.bmj.com
Constrictive pericarditis (CP) is a recognised, but unusual cause of chronic ascites. 1 2
Patients with pericardial constriction may present to non-cardiological specialties, 3 4 with …

[HTML][HTML] Why do I get side effects? Personalized (N-of-1) trials for statin intolerance and the nocebo effect

JP Howard, FA Wood, DP Francis - Harvard data science review, 2022 - ncbi.nlm.nih.gov
The ability of statins to reduce the morbidity and mortality of cardiovascular disease has
ensured that they are among the most prescribed drugs in modern medicine. Unfortunately …

Response to “Drucebo effect–the challenge we should all definitely face!”

JP Howard, DP Francis - Archives of Medical Science: AMS, 2021 - ncbi.nlm.nih.gov
We thank Professors Banach and Penson for their letter. They make an excellent point that
symptoms are, by definition, subjective, and therefore best recorded contemporaneously, for …

[PDF][PDF] Why Do I Get Side E ects? Personalized (N-of-1) Trials for Statin Intolerance and the Nocebo E ect

JP Howard, FA Wood, DP Francis - scholar.archive.org
The ability of statins to reduce the morbidity and mortality of cardiovascular disease has
ensured that they are among the most prescribed drugs in modern medicine. Unfortunately …

TCT-202

JP Howard, Z Buckhoree, DA Jones, SM Gallagher… - core.ac.uk
TCT-203: No Difference In Long-term Major Adverse Cardiac Event Rates Between
Paclitaxel-eluting and Sirolimus-eluting Stents Page 1 TUESDAY, NOVEMBER 8, 2011, 8:00 …

Large mediastinal nodular ganglioneuroblastoma in a child from Africa

S Guarino, C Astini, JP Howard… - Annali Italiani di …, 2012 - annaliitalianidichirurgia.it
ANNALI 729_1847 online:ANNALI 102 Page 1 Large mediastinal nodular ganglioneuroblastoma
in a child from Africa aheadofprint 27 September 2012 - Ann. Ital. Chir., 83, 6, 2012 543 …

[CITATION][C] No Difference In Long-term Major Adverse Cardiac Event Rates Between Paclitaxel-eluting and Sirolimus-eluting Stents

JP Howard, Z Buckhoree… - JOURNAL OF …, 2011 - … INC 360 PARK AVE SOUTH, NEW …